Halozyme Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell HALO and other ETFs, options, and stocks.

About HALO

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. 

CEO
Helen I. Torley
CEOHelen I. Torley
Employees
423
Employees423
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1998
Founded1998
Employees
423
Employees423

HALO Key Statistics

Market cap
7.94B
Market cap7.94B
Price-Earnings ratio
26.19
Price-Earnings ratio26.19
Dividend yield
Dividend yield
Average volume
1.39M
Average volume1.39M
High today
High today
Low today
Low today
Open price
$67.55
Open price$67.55
Volume
0.00
Volume0.00
52 Week high
$82.22
52 Week high$82.22
52 Week low
$47.50
52 Week low$47.50

Stock Snapshot

As of today, Halozyme Therapeutics(HALO) shares are valued at $66.64. The company's market cap stands at 7.94B, with a P/E ratio of 26.19.

On 2026-04-14, Halozyme Therapeutics(HALO) stock opened at $67.55, reached a high of —, and a low of —.

Halozyme Therapeutics(HALO) shares are trading with a volume of 0, against a daily average of 1.39M.

In the last year, Halozyme Therapeutics(HALO) shares hit a 52-week high of $82.22 and a 52-week low of $47.50.

In the last year, Halozyme Therapeutics(HALO) shares hit a 52-week high of $82.22 and a 52-week low of $47.50.

HALO News

Simply Wall St 2d
A Look At Halozyme Therapeutics Valuation After New Vertex Collaboration And Licensing Deal

Halozyme Therapeutics (HALO) is back in focus after announcing a global exclusive collaboration and license agreement with Vertex Pharmaceuticals for its Hyperc...

A Look At Halozyme Therapeutics Valuation After New Vertex Collaboration And Licensing Deal
Simply Wall St 4d
Halozyme Vertex Hypercon Deal Opens New Royalty And Growth Pathways

Halozyme Therapeutics (NasdaqGS:HALO) announced a global exclusive collaboration and license agreement with Vertex Pharmaceuticals for its Hypercon technology....

Halozyme Vertex Hypercon Deal Opens New Royalty And Growth Pathways
Investing.com 7d
Halozyme Therapeutics CEO Helen Torley sells $634,981 in stock - Investing.com

...

Halozyme Therapeutics CEO Helen Torley sells $634,981 in stock - Investing.com

Analyst ratings

60%

of 10 ratings
Buy
60%
Hold
30%
Sell
10%

People also own

Based on the portfolios of people who own HALO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.